Total RNA was extracted from glioma tissues and cell lines using
TRIzol reagent (Thermo Fisher Scientific, USA). Using a
reverse transcription kit (Promega, USA), the RNA (3 μg) was reverse transcribed into cDNAs with a reverse transcription system of 20 μL. Quantitative polymerase chain reaction (qPCR) was conducted using
2 × SYBR Green qPCR Master Mix (Low ROX) (Cat #: B21702, Bimake, USA). The reaction mixture volume was 20 μL, including 10 μL of
2 × SYBR Green qPCR Master Mix (Low ROX), 6 μL of nuclease-free water, 0.2 μM of each primer and 2 μL of cDNA products. The PCR cycling conditions were as follows: 95 °C for 3 min, 95 °C for 15 s, and 60 °C for 40 s for 1 cycle and 95 °C for 15 s, 60 °C for 1 min, and 95 °C for 1 s for 40 cycles followed by the melting curve stage. Relative gene expression was obtained using the 2
−ΔΔCT method. A t test was used for statistical analyses, and P < 0.05 was considered statistically significant.
The following primer sequences were used:
GAPDH
Forward: 5′-GGTGGTCTCCTCTGACTTCAACA-3′,
Reverse: 5′-GTTGCTGTAGCCAAATTCGTTGT-3’,
CTHRC1
Forward: 5′-GGACCAAGGAAGCCCTGAAAT-3’, and.
Reverse: 5’-AGCAACATCCACTAATCCAGCA-3’.
The relative standard curve method was used to analyze the data, which were normalized to GAPDH.
Peng D., Wei C., Zhang X., Li S., Liang H., Zheng X., Jiang S, & Han L. (2021). Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers. Cancer Cell International, 21, 566.